S&P 500 Futures
(0.10%) 5 522.50 points
Dow Jones Futures
(0.14%) 39 898 points
Nasdaq Futures
(0.21%) 19 793 points
Oil
(-0.02%) $81.61
Gas
(0.53%) $2.83
Gold
(-0.25%) $2 338.50
Silver
(0.22%) $29.59
Platinum
(0.42%) $1 006.00
USD/EUR
(0.03%) $0.932
USD/NOK
(-0.05%) $10.53
USD/GBP
(0.01%) $0.788
USD/RUB
(-0.85%) $87.25

Aktualne aktualizacje dla BioNTech SE [BNTX]

Giełda: NASDAQ Sektor: Healthcare Branża: Biotechnology
Ostatnio aktualizowano24 birž. 2024 @ 23:00

2.33% 86.61

KUPNO 879 min ago

@ €86.70

Wydano: 24 birž. 2024 @ 19:18


Zwrot: -0.10%


Poprzedni sygnał: birž. 21 - 21:10


Poprzedni sygnał: Sprzedaż


Zwrot: 2.93 %

Live Chart Being Loaded With Signals

Commentary (24 birž. 2024 @ 23:00):
Our systems believe the stock currently is overvalued by -0.15% compare to its pairs and should correct downwards.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer...

Stats
Dzisiejszy wolumen 1.12M
Średni wolumen 712 112
Kapitalizacja rynkowa 20.59B
EPS €-1.310 ( Q1 | 2024-05-06 )
Następna data zysków ( €-1.980 ) 2024-08-05
Last Dividend €2.26 ( 2022-06-02 )
Next Dividend €0 ( N/A )
P/E 169.82
(Sector) 42.63
(Industry) 24.32
ATR14 €1.890 (2.18%)
AADI 3.55%
ABCL -3.79%
ABCM 0.04%
ABEO -5.02%
ABIO -0.29%
ABOS -3.03%
ABSI 0.66%
ABUS 0.66%
ABVX 2.61%
ACAD 3.79%
ACER -17.95%
ACET 9.49%
ACGN 1.29%
ACHL 0.22%
ACHV -4.83%
ACIU 2.47%
ACLX -0.09%
ACRV -5.30%
ACST -0.31%
ACXP -2.15%
ADAG 0.69%
ADAP -1.06%
ADGI 0.87%
ADIL 2.68%
ADMA 0.09%
ADPT 1.54%
ADTX -2.08%
ADVM 1.63%
ADXN -5.75%
AEON -7.34%
AEZS -1.10%
AFMD 1.02%
AGEN 4.60%
AGIO 0.02%
AGLE 6.66%
AGTC 0.00%
AIKI 0.85%
AIMDW -13.88%
AKBA -0.69%
AKRO 2.80%
AKTX -1.08%
AKUS 0.00%
ALBO 0.00%
ALDX -5.46%
ALEC 0.44%
ALGS -4.88%
ALKS -1.28%
ALLK 8.11%
ALLO 2.35%
ALLR -28.40%
ALNA 3.16%
ALNY 34.52%
ALPN 0.02%
ALPX 0.00%
ALRN -1.60%
ALT 11.39%
ALVR 4.92%
ALXN 0.00%
ALXO -0.15%
ALZN -7.26%
AMRN 2.72%
AMTI -3.13%
ANAB 0.21%
ANEB -1.49%
ANGN 0.00%
ANIX -0.79%
ANL 0.29%
ANNX -4.22%
ANPC -3.15%
APGE 2.63%
APGN 8.48%
APGNW 30.65%
APLM 9.95%
APLS 0.92%
APLT 1.76%
APM 1.73%
APOP 0.38%
APRE 3.24%
APTO -2.37%
APTX 3.17%
APVO 1.15%
ARAV -13.39%
ARCT -0.44%
ARDS 2.49%
ARDX 1.46%
ARGX 11.69%
ARNA 0.00%
ARPO -0.90%
ARQT 4.59%
ARTL -2.71%
ARTLW 0.00%
ARVN -0.99%
ARWR 6.82%
ASLN -2.99%
ASMB 0.38%
ASND 1.20%
ATAI 4.48%
ATHA 1.28%
ATHE 2.27%
ATHX -33.50%
ATNF 2.05%
ATOS -5.31%
ATRA 0.67%
ATXI 9.52%
ATXS -2.65%
AUPH 2.35%
AURA -1.25%
AUTL -2.87%
AVBP -0.78%
AVEO 0.00%
AVIR 1.45%
AVRO -1.41%
AVTE -3.85%
AVTX 2.99%
AVXL 3.19%
AXLA 0.00%
AXSM 2.76%
AYLA 0.00%
AZRX 2.07%
BBI 2.17%
BBIO -15.94%
BCAB 3.31%
BCDA -5.67%
BCDAW -39.75%
BCEL 0.00%
BCLI 2.70%
BCRX -2.34%
BCTX -7.44%
BCTXW -18.26%
BCYC 0.10%
BDRX -15.63%
BDTX 0.83%
BEAM 8.24%
BFRA -2.91%
BGNE 1.95%
BIOR 1.50%
BIVI 0.96%
BLCM -6.68%
BLI -5.88%
BLPH 0.00%
BLRX 3.39%
BLTE 0.27%
BLU 0.03%
BLUE 13.45%
BMEA 5.51%
BMRN 1.62%
BNOX 2.99%
BNTC 4.80%
BNTX 2.33%
BOLD 13.42%
BOLT -1.45%
BPMC 1.79%
BPTH 0.88%
BPTS -13.47%
BRNS 0.00%
BRTX 1.72%
BTAI 4.39%
BTTX 0.00%
BTX 0.05%
BVXV 0.74%
BXRX 7.39%
BYSI -1.78%
CABA -1.53%
CADL 1.82%
CALA 0.00%
CALC -1.87%
CALT 1.83%
CAPR 1.91%
CARA 22.71%
CARM 9.80%
CASI 7.65%
CATB -6.97%
CBAY 0.03%
CBIO -2.65%
CBLI -7.31%
CBUS -4.40%
CCCC 11.08%
CCXI 0.00%
CDAK 0.00%
CDIO -0.17%
CDIOW 36.86%
CDMO -4.38%
CDMOP 0.04%
CDT -7.05%
CDTTW -23.91%
CDTX -2.84%
CDXC -6.59%
CDXS 2.04%
CELC 4.58%
CELU 0.66%
CELUW 11.18%
CERC -1.68%
CERE -0.55%
CERO 2.09%
CEROW -22.90%
CFRX -27.95%
CGEM -0.34%
CGEN -5.08%
CGON 1.50%
CGTX -2.63%
CHMA -6.00%
CHRS -2.40%
CINC 0.00%
CING 4.73%
CINGW 73.79%
CKPT 15.56%
CLBS -16.75%
CLDX 2.55%
CLGN 6.22%
CLLS 1.06%
CLNN -3.46%
CLNNW -33.25%
CLRB 0.00%
CLSD 0.00%
CLSN -0.68%
CLVS 0.00%
CMMB 8.57%
CMND -7.59%
CMPI 0.00%
CMPX 0.91%
CMRA 0.00%
CMRAW 33.33%
CMRX 1.85%
CNCE 0.00%
CNSP 12.63%
CNST 0.00%
CNTA -2.31%
CNTB -6.25%
CNTX 0.93%
COCP -1.88%
COEPW 0.00%
COGT 1.14%
CORT 1.83%
COYA -2.48%
CPRX -1.28%
CRBP 2.42%
CRBU 8.72%
CRDF -3.67%
CRGX 4.50%
CRIS 3.02%
CRNX 0.18%
CRSP 3.02%
CRTX 2.63%
CRVO 0.40%
CRVS 2.81%
CSBR -1.20%
CTCX -7.84%
CTIC 0.06%
CTMX 3.10%
CTNM 3.23%
CTXR 4.68%
CUE 8.89%
CVAC 6.44%
CVKD 6.24%
CWBR 0.00%
CYAD -12.96%
CYCC -5.01%
CYCCP 4.03%
CYCN 6.69%
CYT -2.27%
CYTK 0.71%
CYTO 2.61%
DARE 1.96%
DAWN -1.10%
DBTX -0.81%
DBVT -1.80%
DFFN 10.28%
DICE 0.06%
DMAC 2.78%
DNLI 1.24%
DNTH -0.04%
DOMH -2.63%
DRMA 12.50%
DRMAW -1.25%
DRNA 0.00%
DRTS 1.62%
DRTSW 0.00%
DRUG -3.77%
DSGN -0.59%
DTIL 0.85%
DYAI -9.66%
EARS -1.77%
EDIT -0.59%
EDSA -0.11%
EFTR -75.81%
EFTRW -96.33%
EIGR -9.21%
ELAB 0.86%
ELDN -4.40%
ELEV -4.30%
ELOX 0.00%
ELTX 6.89%
ELVN 1.87%
ELYM -8.69%
ENGN -9.67%
ENGNW -7.87%
ENLV 3.68%
ENOB 1.79%
ENSC 4.98%
ENTA 2.43%
ENTO -2.13%
ENTX 1.98%
ENVB 9.19%
EPIX -1.02%
EPRX 0.57%
EPZM 0.00%
EQ 2.52%
EQRX -2.09%
EQRXW 0.00%
ERAS 2.37%
ERNA -4.64%
ERYP 1.30%
ESLA -0.50%
ESLAW 0.00%
ETNB -0.82%
ETON -0.60%
ETTX 0.00%
EVAX -5.28%
EVGN -2.18%
EVLO 0.00%
EWTX -1.99%
EXAI -2.78%
EXEL 0.54%
EYEG 0.11%
EYEN 2.28%
EYPT 0.59%
FATE 2.13%
FBIO -3.95%
FBIOP 0.59%
FBLG 5.49%
FBRX 0.27%
FDMT 1.35%
FENC -1.09%
FGEN 6.19%
FHTX 0.38%
FIXX 0.77%
FMTX 0.00%
FNCH -6.77%
FOLD -0.89%
FREQ 4.76%
FRLN 0.15%
FRTX -4.51%
FSTX 0.00%
FTRE -0.65%
FULC -5.09%
FUSN 0.00%
FWBI 4.59%
FWP 0.00%
GALT -8.97%
GANX 0.00%
GBIO 1.45%
GBT 0.01%
GDTC 5.61%
GERN -1.29%
GHRS 0.42%
GLMD -1.83%
GLPG 1.67%
GLSI -4.73%
GLTO 5.51%
GLUE 4.96%
GLYC 3.61%
GMAB -0.81%
GMDA -18.25%
GMTX 0.00%
GNCA -85.71%
GNFT 1.29%
GNLX 10.68%
GNPX 0.00%
GNTA 7.74%
GOSS 27.09%
GOVX 30.04%
GOVXW 49.24%
GPCR -4.15%
GRAY -10.80%
GRCL 0.05%
GRNA -0.03%
GRNAW 8.91%
GRPH -2.75%
GRTS 4.76%
GRTX 40.48%
GTHX -10.48%
GUTS 5.77%
GXGXW 41.67%
GYRE -3.28%
HALO 0.99%
HARP 0.09%
HCWB 10.69%
HEPA 5.42%
HGEN -84.62%
HILS 5.66%
HLVX 2.75%
HOOK -1.07%
HOTH 0.67%
HOWL -9.38%
HRMY -0.10%
HRTX -1.55%
HSTO 0.00%
HUMA -1.35%
HUMAW 5.19%
IBRX 1.10%
ICCC -0.22%
ICPT 0.21%
ICU 10.12%
ICUCW 14.68%
ICVX -0.91%
IDRA -23.04%
IDYA 0.03%
IFRX 8.44%
IGMS 0.00%
IKNA -2.33%
IKT -5.00%
IMAB 2.38%
IMCR -0.28%
IMGN 0.02%
IMGO 0.00%
IMMP -2.92%
IMMX 11.76%
IMNM -4.02%
IMNN -4.46%
IMPL -27.27%
IMRA 15.96%
IMRN 12.11%
IMRX 4.20%
IMTX -1.37%
IMTXW -14.50%
IMUX -0.90%
IMV 0.00%
IMVT 0.18%
INAB -0.84%
INBX 2.18%
INCY 0.84%
INDP -1.33%
INFI -52.38%
INKT -1.62%
INM 9.72%
INMB 1.62%
INO -1.61%
INSM 0.65%
INTS 4.74%
INVA 0.63%
INZY 0.67%
IOBT 0.00%
IONS 6.81%
IOVA 1.87%
IPA -1.92%
IPHA -5.16%
IPSC -6.29%
IRON 1.81%
ISEE 0.38%
ITOS 0.61%
ITRM -5.65%
IVA -0.71%
IVVD 2.42%
JAGX -3.32%
JANX 5.52%
JAZZ 1.72%
JNCE 0.00%
JSPR 1.72%
JSPRW 4.71%
JUNS 0.00%
JUNSW 0.00%
KA 13.13%
KALV -0.17%
KDNY 0.22%
KMPH -0.34%
KNSA 1.40%
KNTE -0.38%
KOD 3.41%
KPRX 9.68%
KPTI 12.76%
KRBP -0.40%
KRON -6.48%
KROS 0.09%
KRRO -0.76%
KRTX 0.03%
KRYS 1.97%
KTRA 6.15%
KTTA 4.85%
KTTAW -5.17%
KURA 0.67%
KYMR -1.69%
KYTX 2.07%
KZIA -15.51%
KZR 1.12%
LABP 0.57%
LBPH 0.05%
LBPS 0.00%
LBPSW 14.81%
LEGN 1.13%
LENZ -1.52%
LEXX -1.49%
LEXXW -0.19%
LGND 0.72%
LGNDV 0.00%
LGVN -12.73%
LIAN -8.28%
LIFE 2.70%
LIPO 10.88%
LIXT -1.57%
LIXTW 0.00%
LJPC -0.32%
LMNL 0.12%
LOGC 1.27%
LPCN 3.56%
LPTX -2.08%
LQDA 3.28%
LRMR -10.33%
LSTA -3.26%
LTRN -5.78%
LUMO 1.79%
LVTX 0.27%
LXEO 4.94%
LXRX -2.16%
LYEL 3.41%
LYRA -2.78%
MACK 0.10%
MBIO 2.70%
MBRX -3.48%
MCRB -2.19%
MDGL 2.00%
MDNA -13.16%
MDWD 7.88%
MDXG -1.02%
MEIP -2.80%
MESO -3.28%
MGNX 2.97%
MGTA -7.74%
MGTX -3.18%
MGX 0.56%
MIRM 8.74%
MIRO 0.59%
MIST 0.72%
MITO 0.00%
MLEC -5.36%
MLECW 90.24%
MLND -5.36%
MLTX 0.73%
MLYS 4.90%
MNKD 6.26%
MNMD 0.27%
MNOV 0.00%
MNPR 15.76%
MOLN -25.10%
MOR -0.11%
MORF 10.26%
MREO -5.53%
MRKR 9.03%
MRNA 2.70%
MRNS 3.01%
MRSN 3.76%
MRTX -0.17%
MRUS 3.77%
MRVI -2.35%
MTCR -1.29%
MTEM -4.59%
MTP -18.50%
MURA -0.62%
MYMD -4.12%
NAMS 8.93%
NAMSW 26.87%
NAUT -8.57%
NBRV 0.71%
NBSE -1.56%
NBTX 4.81%
NCNA -0.34%
NERV -5.52%
NEXI -2.44%
NGM -1.28%
NGNE 2.39%
NKGN 0.00%
NKGNW 8.00%
NKTR 0.86%
NKTX 1.82%
NLSP -5.16%
NLSPW 28.30%
NMRA 0.00%
NMTR -42.97%
NOVN -24.84%
NRBO 0.49%
NRIX -1.27%
NRSN -3.99%
NRSNW 0.00%
NRXP 0.75%
NRXPW 0.00%
NRXS -0.78%
NTBL 0.36%
NTEC -12.45%
NTHI 0.00%
NTLA 3.22%
NTRBW 0.00%
NUVL 1.72%
NVAX 0.14%
NVCT 2.13%
NVIV -34.28%
NXTC 3.70%
NYMX -0.05%
OABI 1.75%
OABIW -3.65%
OBIO 9.02%
OBSV 0.00%
OCEA 7.75%
OCGN -5.26%
OCS 1.37%
OCUL 4.48%
OCUP 1.27%
ODT -4.27%
OKYO -1.63%
OLMA 2.15%
OMER 2.90%
OMGA -0.41%
ONCO -6.85%
ONCR -3.08%
ONCS 31.87%
ONCT -1.85%
ONCY 0.00%
ONTX -0.47%
ONVO -2.28%
OPNT 0.00%
OPT -4.93%
ORGS -3.25%
ORIC -1.11%
ORMP -3.04%
ORPH 0.00%
ORTX 0.30%
OSMT -1.77%
OTIC -92.64%
OTLK -2.62%
OVID 1.28%
OYST 0.00%
PALI -3.95%
PASG 0.00%
PBLA -4.76%
PBM -4.74%
PBYI -2.34%
PCSA 0.51%
PCVX 1.12%
PDSB 8.33%
PEPG 4.57%
PGEN 4.55%
PHAR 13.76%
PHAS 0.00%
PHAT -2.26%
PHIO 3.65%
PHIOW 36.47%
PHVS -4.62%
PHXM -5.20%
PIRS -5.56%
PKBO 0.00%
PKBOW 999 900.00%
PLRX 3.28%
PLUR -0.44%
PMN -0.63%
PMVP 4.64%
PNT 0.16%
PPBT 5.78%
PRAX -2.61%
PRDS 0.93%
PRLD 2.88%
PROG -3.47%
PROK -7.60%
PRQR -3.51%
PRTA 0.56%
PRTC -6.90%
PRTG -0.04%
PRTK 1.83%
PRVB 0.00%
PSTI -2.91%
PSTV -11.11%
PSTX -1.08%
PTCT -2.05%
PTE -0.82%
PTGX -0.78%
PTIXW -5.10%
PULM -2.53%
PXMD 0.00%
PYPD -1.97%
PYXS -5.34%
QLGN -8.10%
QNCX 0.71%
QNRX 1.44%
QSI 0.84%
QSIAW 1.20%
QTTB -0.71%
QURE -1.09%
RAIN -1.63%
RANI -0.96%
RAPT 3.18%
RARE -0.45%
RCKT 7.03%
REGN 1.02%
RENB 1.27%
REPL 3.06%
RETA 0.02%
REUN -0.89%
REVB 13.74%
REVBU 3.46%
REVBW 50.29%
RGLS -18.33%
RGNX 6.41%
RIGL 0.65%
RLAY -0.58%
RLMD -0.99%
RLYB 5.48%
RNA 1.69%
RNAC 1.05%
RNAZ 5.27%
RNXT 4.09%
ROIV 2.06%
ROIVW 4.56%
RPHM 0.00%
RPRX 0.74%
RPTX 0.28%
RUBY 2.70%
RVLP -32.05%
RVMD 0.76%
RVMDW 17.51%
RVNC -3.38%
RVPH 2.40%
RVPHW 1.92%
RXDX 0.09%
RXRX 5.54%
RYTM 1.58%
RYZB 0.02%
RZLT 7.85%
SABS 4.23%
SABSW -35.81%
SAGE 3.86%
SANA 0.54%
SAVA -1.10%
SAVAW 0.00%
SBBP 1.52%
SBTX 1.03%
SCNI -6.67%
SCPH 1.24%
SCPS 0.00%
SEEL -2.49%
SEER 1.76%
SELB -8.00%
SESN 7.29%
SGEN -0.07%
SGMO 5.62%
SGMT 6.87%
SGTX -2.56%
SIOX 22.63%
SLDB 2.48%
SLGL 0.59%
SLN 3.61%
SLNO -2.60%
SLRX -3.97%
SLS -0.82%
SMMT 0.88%
SNDX -1.25%
SNGX -2.31%
SNPX 5.67%
SONN -6.53%
SPPI -0.49%
SPRB 5.39%
SPRC -2.42%
SPRO -2.92%
SRNE 15.79%
SRPT 1.95%
SRRA 0.00%
SRRK -0.47%
SRZN 5.26%
STAB 0.00%
STOK 0.70%
STRO -4.95%
STSA 0.00%
STTK -9.50%
SURF -0.93%
SVRA -5.67%
SWTX -0.17%
SYBX 2.01%
SYRS 4.12%
TALS -0.73%
TARA -1.33%
TARS 1.36%
TBPH 0.23%
TCBP -8.11%
TCDA 0.00%
TCON -1.60%
TCRR 0.00%
TCRT -3.84%
TCRX 2.92%
TECH 1.13%
TENX 9.03%
TERN 4.01%
TFFP 9.20%
TGTX 4.31%
THRX 0.12%
TIL -3.68%
TLC 0.00%
TLSA 14.49%
TNGX 0.50%
TNXP -8.46%
TNYA -0.96%
TPST 2.96%
TRDA -4.11%
TRVI -2.22%
TRVN -13.99%
TSHA -10.14%
TSVT 3.76%
TTNP -14.84%
TVTX 6.57%
TYRA 0.35%
UBX 0.36%
UNCY 7.44%
URGN 5.81%
UTHR 0.92%
VACC 11.36%
VALN 12.99%
VAXX -10.53%
VBIV 3.44%
VBLT -8.77%
VCEL 2.64%
VCNX -0.49%
VCYT 1.77%
VERA -2.79%
VERU 9.04%
VERV -0.19%
VIGL 0.52%
VINC -1.38%
VIR 0.22%
VIRI -1.85%
VIRX -5.63%
VKTX -1.18%
VLON -13.04%
VNDA -2.29%
VOR 4.20%
VRCA -4.56%
VRDN 5.09%
VRNA 4.60%
VRPX -4.95%
VRTX 1.33%
VSTM -1.90%
VTGN -3.58%
VTVT 0.00%
VTYX -0.80%
VXRT 5.82%
VYGR -0.43%
VYNE -4.95%
VYNT 7.78%
WINT 7.90%
WVE -0.76%
XBIO -5.83%
XBIT -12.02%
XCUR -3.35%
XENE -0.21%
XERS 0.00%
XFOR 0.00%
XLO 2.47%
XLRN 0.00%
XNCR 1.46%
XOMA 5.64%
XOMAO -0.20%
XOMAP -0.76%
XRTX -2.38%
YMAB 0.83%
ZGNX 0.00%
ZIOP -0.88%
ZLAB 0.97%
ZNTL -3.16%
ZSAN 0.00%
Korelacja (AI algo v.1.1b): Overvalued: -0.15% €86.75 paired level. (Algorytm śledzi zmiany najbardziej skorelowanych akcji w czasie rzeczywistym i natychmiast aktualizuje)

Wolumen Korelacja

Długi: -0.39 (neutral)
Krótki: -0.70 (moderate negative)
Signal:(54) Neutral

BioNTech SE Korelacja

10 Najbardziej pozytywne korelacje
OZEM1
HPCO0.949
KRSOX0.919
OPTX0.916
ATXS0.91
UXIN0.908
NUVO0.906
NYXH0.904
LDTC0.904
CRGX0.897
10 Najbardziej negatywne korelacje
INDH-0.895
PPRUX-0.876
ADSEW-0.875
SFBC-0.874
BOTT-0.869
PSTR-0.867
ELTX-0.867
CCSB-0.865
VCEL-0.863
KRUS-0.862

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BioNTech SE Korelacja - Waluta/Towar

The country flag 0.37
( neutral )
The country flag 0.21
( neutral )
The country flag 0.00
( neutral )
The country flag 0.40
( neutral )
The country flag 0.30
( neutral )
The country flag -0.32
( neutral )

BioNTech SE Finanse

Annual 2023
Przychody: €3.82B
Zysk brutto: €3.22B (84.29 %)
EPS: €3.79
FY 2023
Przychody: €3.82B
Zysk brutto: €3.22B (84.29 %)
EPS: €3.79
FY 2022
Przychody: €17.31B
Zysk brutto: €12.78B (73.82 %)
EPS: €38.08
FY 2021
Przychody: €18.98B
Zysk brutto: €15.12B (79.66 %)
EPS: €40.63

Financial Reports:

No articles found.

BioNTech SE Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

BioNTech SE Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 7.79 - good (77.90%) | Divividend Growth Potential Score: 3.87 - No dividend growth expected in the near future
Information
First Dividend €2.26 2022-06-02
Last Dividend €2.26 2022-06-02
Next Dividend €0 N/A
Payout Date 2022-06-17
Next Payout Date N/A
# dividends 1 --
Total Paid Out €2.26 --
Avg. Dividend % Per Year 0.16% --
Score 1.82 --
Div. Sustainability Score 7.79
Div.Growth Potential Score 3.87
Div. Directional Score 5.83 --
Next Divdend (Est)
(2024-06-25)
€0 Estimate 0.00 %
Dividend Stability
0.04 Very Bad
Dividend Score
1.82
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield
2022 €2.26 0.98%
2023 €0 0.00%
2024 €0 0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Dividend History

Ex Date Amount Declaration Date Record Date Payment Date
02 Jun 2022 €2.26 27 Apr 2022 03 Jun 2022 17 Jun 2022

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
OXLC Dividend Diamond 2024-09-16 Monthly 14 15.03% 9.60
DMLP Dividend Diamond 2024-04-26 Quarterly 22 10.71% 9.35
OXSQ Dividend Diamond 2024-09-16 Monthly 21 12.73% 9.02
ARLP Dividend Royal 2024-05-07 Quarterly 26 9.67% 8.87
PNNT Dividend Royal 2024-06-14 Monthly 18 9.49% 8.82
MFIC Dividend Royal 2024-06-11 Quarterly 21 10.89% 8.79
SPOK Dividend Royal 2024-05-23 Quarterly 20 8.73% 8.72
PSEC Dividend Royal 2024-06-25 Monthly 21 9.03% 8.65
SBLK Dividend Royal 2024-06-06 Quarterly 17 13.10% 8.63
GBDC Dividend Royal 2024-11-29 Bi-Monthly 15 8.53% 8.62

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.04141.5009.1710.00[0 - 0.5]
returnOnAssetsTTM0.005081.2009.8310.00[0 - 0.3]
returnOnEquityTTM0.005651.500-1.048-1.572[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM11.380.80010.008.00[1 - 3]
quickRatioTTM10.950.80010.008.00[0.8 - 2.5]
cashRatioTTM5.591.50010.0010.00[0.2 - 2]
debtRatioTTM0.0106-1.5009.82-10.00[0 - 0.6]
interestCoverageTTM-17.521.000-7.60-7.60[3 - 30]
operatingCashFlowPerShareTTM23.832.002.064.11[0 - 30]
freeCashFlowPerShareTTM20.552.0010.0010.00[0 - 20]
debtEquityRatioTTM0.0118-1.5009.95-10.00[0 - 2.5]
grossProfitMarginTTM0.4751.0005.425.42[0.2 - 0.8]
operatingProfitMarginTTM-0.1731.000-5.45-5.45[0.1 - 0.6]
cashFlowToDebtRatioTTM24.261.00010.0010.00[0.2 - 2]
assetTurnoverTTM0.1230.800-2.52-2.01[0.5 - 2]
Total Score7.79

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM168.491.00010.000[1 - 100]
returnOnEquityTTM0.005652.50-0.674-1.572[0.1 - 1.5]
freeCashFlowPerShareTTM20.552.003.1510.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM23.832.002.064.11[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM6.361.50010.000[0.5 - 2]
operatingCashFlowSalesRatioTTM2.101.00010.000[0.1 - 0.5]
Total Score3.87

BioNTech SE Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej

Total Execution Time: 2.4309270381927 seconds
Number of API calls: 3
Number of DB calls: 9